Top Markets
#1 Ontology Gas Ontology Gas +26.18%
#2 Verus Coin Verus Coin +22.50%
#3 EXOD EXOD +22.08%
#4 Status Status +19.02%
#5 ETHGas ETHGas +17.85%
#6 Bitway Bitway +15.81%
#7 Geodnet Geodnet +14.32%
#8 Curve DAO Curve DAO +11.70%
#9 Derive Derive +11.25%
#10 The Black Bull The Black Bull +11.14%
Coin of the day
Ontology Gas Ontology Gas
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Carna Biosciences, Inc. Carna Biosciences, Inc.

Carna Biosciences, Inc.

4572
Classificação em ações #25406
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a... Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Preço da ação
$2.62
Valor de mercado
$50.19M
Variação (1 dia)
-1.47%
Variação (1 ano)
77.21%
País
JP
Negociar Carna Biosciences, Inc. (4572)

Categoria

Healthcare
Histórico de dividendos de Carna Biosciences, Inc. (4572)
Carna Biosciences, Inc. (símbolo da ação: 4572) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Carna Biosciences, Inc. (4572) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US